https://www.sciencedaily.com/news/health_medicine/vioxx/ Vioxx News. Read about side effects of Vioxx, Bextra and Celebrex. Read the latest medical and scientific information on Vioxx and the link between certain medications and heart attacks. en-us Fri, 06 Mar 2026 01:59:27 EST Fri, 06 Mar 2026 01:59:27 EST 60 https://www.sciencedaily.com/images/scidaily-logo-rss.png https://www.sciencedaily.com/news/health_medicine/vioxx/ For more science news, visit ScienceDaily. https://www.sciencedaily.com/releases/2026/01/260120000323.htm Ibuprofen may be doing more than easing aches and pains—it could also help reduce the risk of some cancers. Studies have linked regular use to lower rates of endometrial and bowel cancer, likely because the drug dampens inflammation that fuels tumor growth. Researchers have even found it can interfere with genes cancer cells rely on to survive. Still, experts warn that long-term use carries risks and shouldn’t replace proven prevention strategies. Tue, 20 Jan 2026 03:47:11 EST https://www.sciencedaily.com/releases/2026/01/260120000323.htm https://www.sciencedaily.com/releases/2025/09/250928095611.htm A groundbreaking international study has shown that a 2-in-1 budesonide-formoterol inhaler is far more effective than the standard salbutamol inhaler in children with mild asthma, cutting attacks by nearly half. Sun, 28 Sep 2025 10:29:35 EDT https://www.sciencedaily.com/releases/2025/09/250928095611.htm https://www.sciencedaily.com/releases/2025/04/250414124347.htm Patients who receive an add-on medication soon after a heart attack have a significantly better prognosis than those who receive it later, or not all, new research suggests. Mon, 14 Apr 2025 12:43:47 EDT https://www.sciencedaily.com/releases/2025/04/250414124347.htm https://www.sciencedaily.com/releases/2025/04/250401131014.htm Nearly 40% of patients diagnosed with type 2 diabetes imperil their health by stopping their medication within the first year, diabetes experts warn. Tue, 01 Apr 2025 13:10:14 EDT https://www.sciencedaily.com/releases/2025/04/250401131014.htm https://www.sciencedaily.com/releases/2025/02/250226125001.htm A microbiologist has written an article on the dangers posed by raw sewage in the seas around the UK. Wed, 26 Feb 2025 12:50:01 EST https://www.sciencedaily.com/releases/2025/02/250226125001.htm https://www.sciencedaily.com/releases/2025/01/250128124325.htm A data analysis from a randomized clinical trial for stage 3 colon cancer patients found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment. Tue, 28 Jan 2025 12:43:25 EST https://www.sciencedaily.com/releases/2025/01/250128124325.htm https://www.sciencedaily.com/releases/2024/07/240729125211.htm If current guidelines for cholesterol and high blood pressure treatment remain unchanged, a newly unveiled heart risk calculator would render 16 million people ineligible for preventive therapy. Loss of eligibility for cholesterol and blood pressure medicines could lead to 107,000 more heart attacks and strokes over 10 years but may reduce new diabetes cases by 57,000 over the same period. The findings underscore the importance of reexamining current treatment cutoffs in parallel with new risk estimates to better individualize therapy and improve clinical decisions. Mon, 29 Jul 2024 12:52:11 EDT https://www.sciencedaily.com/releases/2024/07/240729125211.htm https://www.sciencedaily.com/releases/2024/07/240716202304.htm Researchers have identified a new way to make opioids safer, increasing the pain-relieving properties of opioids while decreasing unwanted side effects through the spinal inhibition of a Heat shock protein 90 isoform. Tue, 16 Jul 2024 20:23:04 EDT https://www.sciencedaily.com/releases/2024/07/240716202304.htm https://www.sciencedaily.com/releases/2024/07/240711111352.htm Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer's disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs. Thu, 11 Jul 2024 11:13:52 EDT https://www.sciencedaily.com/releases/2024/07/240711111352.htm https://www.sciencedaily.com/releases/2024/06/240620152233.htm Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, including Hodgkin lymphoma. Checkpoint inhibitor therapies can be thought of as the molecular 'brake release' for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and targeting cancer cells in the body. Thu, 20 Jun 2024 15:22:33 EDT https://www.sciencedaily.com/releases/2024/06/240620152233.htm https://www.sciencedaily.com/releases/2024/06/240606152339.htm Some cancer drugs cause severe side effects because they are not working accurately enough. Biochemists have now discovered why. Thu, 06 Jun 2024 15:23:39 EDT https://www.sciencedaily.com/releases/2024/06/240606152339.htm https://www.sciencedaily.com/releases/2024/04/240425161552.htm A multicenter study has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death. Thu, 25 Apr 2024 16:15:52 EDT https://www.sciencedaily.com/releases/2024/04/240425161552.htm https://www.sciencedaily.com/releases/2023/01/230104231338.htm Moderate levels of two outdoor air pollutants, ozone and fine particulate matter, are associated with non-viral asthma attacks in children and adolescents who live in low-income urban areas. The study also identifies associations between exposure to the two pollutants and molecular changes in the children's airways during non-viral asthma attacks, suggesting potential mechanisms for those attacks. Wed, 04 Jan 2023 23:13:38 EST https://www.sciencedaily.com/releases/2023/01/230104231338.htm https://www.sciencedaily.com/releases/2022/06/220603094902.htm A new study has found that RAAS inhibitors, a class of blood pressure-lowering medicine, may be better at reducing the risk of brain aneurysm rupture. People with a brain aneurysm -- a weakened area of a blood vessel -- who were being treated for high blood pressure with medication from the class of drugs called RAAS inhibitors had a significantly lower risk of a ruptured aneurysm compared to those who took other blood pressure medications. These results indicate that RAAS inhibitors may be preferable to other blood pressure-lowering medications and could inform treatment decisions for people with high blood pressure who have unruptured intracranial aneurysms. Fri, 03 Jun 2022 09:49:02 EDT https://www.sciencedaily.com/releases/2022/06/220603094902.htm https://www.sciencedaily.com/releases/2022/03/220328090017.htm Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumor growth, according to a proof-of-concept study. Mon, 28 Mar 2022 09:00:17 EDT https://www.sciencedaily.com/releases/2022/03/220328090017.htm https://www.sciencedaily.com/releases/2022/03/220307113048.htm Researchers demonstrate that combinations of antiviral drugs inhibiting both polymerase and exonuclease reduce SARS-CoV-2 replication 10 times more than polymerase inhibitors alone. Mon, 07 Mar 2022 11:30:48 EST https://www.sciencedaily.com/releases/2022/03/220307113048.htm https://www.sciencedaily.com/releases/2021/11/211119155504.htm People taking TNF inhibitors, a kind of immunosuppressive drug used to treat rheumatoid arthritis and other autoimmune conditions, produced a weaker and shorter-lived antibody response after two doses of Pfizer's COVID-19 vaccine, according to a new study. A third vaccine dose drove antibody levels back up, indicating that this additional dose may provide protection as the virus's delta variant continues to spread. Fri, 19 Nov 2021 15:55:04 EST https://www.sciencedaily.com/releases/2021/11/211119155504.htm https://www.sciencedaily.com/releases/2021/08/210812161905.htm PARP inhibitors, used to treat patients with cancer of the breast, ovaries, prostate and pancreas, work by inducing persistent DNA gaps in tumor cells with BRCA1 and BRCA2 mutations. The discovery offers the potential to monitor tumors for the development of resistance to PARP inhibitor therapy, and to identify drug combinations that could prevent drug resistance and improve the efficacy of cancer therapies. Thu, 12 Aug 2021 16:19:05 EDT https://www.sciencedaily.com/releases/2021/08/210812161905.htm https://www.sciencedaily.com/releases/2021/07/210726102143.htm In an analysis of almost 3 million patients taking a single high blood pressure medication for the first time, angiotensin receptor blockers (ARBs) were as good as angiotensin-converting enzyme (ACE) inhibitors at preventing cardiovascular events linked to hypertension, including heart attack, stroke and heart failure. 51 possible side effects and safety concerns were examined: The patients taking ARBs were found to be significantly less likely to develop tissue swelling, cough, pancreas inflammation and bleeding in the digestive tract. Mon, 26 Jul 2021 10:21:43 EDT https://www.sciencedaily.com/releases/2021/07/210726102143.htm https://www.sciencedaily.com/releases/2021/01/210111115740.htm COVID-19 patients who also suffer from high blood pressure are more likely to fall severely ill with the disease, which also leaves them at greater risk of death. Scientists have now found that the immune cells of patients with hypertension are already pre-activated, and that this pre-activation is greatly enhanced under COVID-19. Mon, 11 Jan 2021 11:57:40 EST https://www.sciencedaily.com/releases/2021/01/210111115740.htm https://www.sciencedaily.com/releases/2020/12/201207091246.htm A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer. Mon, 07 Dec 2020 09:12:46 EST https://www.sciencedaily.com/releases/2020/12/201207091246.htm https://www.sciencedaily.com/releases/2020/10/201013124153.htm Scientists are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. Tue, 13 Oct 2020 12:41:53 EDT https://www.sciencedaily.com/releases/2020/10/201013124153.htm https://www.sciencedaily.com/releases/2020/10/201002105752.htm Users of widely used drugs against elevated blood pressure or heart problems may have a better chance of surviving severe influenza or pneumonia infections, a new study shows. Fri, 02 Oct 2020 10:57:52 EDT https://www.sciencedaily.com/releases/2020/10/201002105752.htm https://www.sciencedaily.com/releases/2020/09/200901112216.htm Heart patients hospitalized with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to new research. Tue, 01 Sep 2020 11:22:16 EDT https://www.sciencedaily.com/releases/2020/09/200901112216.htm https://www.sciencedaily.com/releases/2020/04/200429191849.htm Use of sodium glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes may help to lower the risk of serious kidney problems, finds a study published by The BMJ today. Wed, 29 Apr 2020 19:18:49 EDT https://www.sciencedaily.com/releases/2020/04/200429191849.htm https://www.sciencedaily.com/releases/2020/04/200410162426.htm A prospective 'PARP inhibitor' drug that has struggled to show effectiveness in clinical trials against cancers can be structurally modified to greatly increase its power to kill tumor cells, researchers say. Fri, 10 Apr 2020 16:24:26 EDT https://www.sciencedaily.com/releases/2020/04/200410162426.htm https://www.sciencedaily.com/releases/2020/02/200205132318.htm About 29 million Americans use over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) to treat pain. Every year in the US, NSAID use is attributed to approximately 100,000 hospitalizations and 17,000 deaths. All of these drugs have benefits and risks, but deciding which one to use is complicated for health care providers and their patients. To assist in clinical decision-making, researchers address cardiovascular risks and beyond, which include gastrointestinal and kidney side effects of pain relievers. Wed, 05 Feb 2020 13:23:18 EST https://www.sciencedaily.com/releases/2020/02/200205132318.htm https://www.sciencedaily.com/releases/2020/01/200114123518.htm A new study shows how resistance to a promising targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma. Tue, 14 Jan 2020 12:35:18 EST https://www.sciencedaily.com/releases/2020/01/200114123518.htm https://www.sciencedaily.com/releases/2019/10/191015131620.htm The aim of immunotherapies is to enable the immune system once again to fight cancer on its own. Drugs known as checkpoint inhibitors are already in clinical use for this purpose. However, they are only effective in about one third of patients. Based on analysis of human tissue samples, a team has now discovered one reason why this is so: an inactive receptor in cancer cells prevents the drugs from reactivating the immune system. Tue, 15 Oct 2019 13:16:20 EDT https://www.sciencedaily.com/releases/2019/10/191015131620.htm https://www.sciencedaily.com/releases/2019/09/190904194443.htm A new meta-analysis has found that SGLT2 inhibitors can reduce the risk of dialysis, transplantation, or death due to kidney disease in people with type 2 diabetes. Wed, 04 Sep 2019 19:44:43 EDT https://www.sciencedaily.com/releases/2019/09/190904194443.htm https://www.sciencedaily.com/releases/2019/08/190822113352.htm First head-to-head comparison of CDK4/6 inhibitors in cell line and animal models of breast cancer reveals important differences, including one drug that exhibits unique, potentially advantageous therapeutic activity. Thu, 22 Aug 2019 11:33:52 EDT https://www.sciencedaily.com/releases/2019/08/190822113352.htm https://www.sciencedaily.com/releases/2019/07/190724110938.htm Drugs currently used to treat less than 10% of breast cancer patients could have broader effectiveness in treating all cancers, including ovarian and prostate cancers. Wed, 24 Jul 2019 11:09:38 EDT https://www.sciencedaily.com/releases/2019/07/190724110938.htm https://www.sciencedaily.com/releases/2019/07/190708092859.htm New research that uncovers the mechanism behind the newest generation of cancer drugs is opening the door for better targeted therapy. PARP inhibitors are molecular targeted cancer drugs used to treat women with ovarian cancer who have the BRCA1 and BRCA2 gene mutations. The drugs are showing promise in late-stage clinical trials for breast cancer, prostate cancer and pancreatic cancer. Mon, 08 Jul 2019 09:28:59 EDT https://www.sciencedaily.com/releases/2019/07/190708092859.htm https://www.sciencedaily.com/releases/2019/04/190424125103.htm In a series of studies that volleyed between large databases and research in zebrafish, investigators have discovered a link between vascular biology and eye disease. The research uncovered an unexpected role for the gene GRIK5, and it showcases a new paradigm for using biobanks, electronic health records and zebrafish to discover the genetic mechanisms that contribute to human disease. Wed, 24 Apr 2019 12:51:03 EDT https://www.sciencedaily.com/releases/2019/04/190424125103.htm https://www.sciencedaily.com/releases/2019/04/190404143634.htm Immunotherapy drugs known as checkpoint inhibitors have revolutionized cancer treatment: many patients with malignancies that until recently would have been considered untreatable are experiencing long-term remissions. Now, researchers have identified a surprising phenomenon that may explain why many cancers don't respond to these drugs, and hints at new strategies to unleash the immune system against disease. Thu, 04 Apr 2019 14:36:34 EDT https://www.sciencedaily.com/releases/2019/04/190404143634.htm https://www.sciencedaily.com/releases/2019/03/190308195635.htm Precision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and could help many more patients benefit from immunotherapy, a new study reveals. Fri, 08 Mar 2019 19:56:35 EST https://www.sciencedaily.com/releases/2019/03/190308195635.htm https://www.sciencedaily.com/releases/2019/02/190226161931.htm Scientists are blasting E. coli bacteria with ionizing radiation once a week to watch evolution happen in real time as the bacteria become radiation resistant. Tue, 26 Feb 2019 16:19:31 EST https://www.sciencedaily.com/releases/2019/02/190226161931.htm https://www.sciencedaily.com/releases/2019/02/190215110326.htm Researchers have discovered a new mechanism for a class of anti-cancer drugs known as E1 inhibitors. Their findings reveal a novel binding site that will promote drug design of more efficient E1 inhibitors. Fri, 15 Feb 2019 11:03:26 EST https://www.sciencedaily.com/releases/2019/02/190215110326.htm https://www.sciencedaily.com/releases/2018/10/181011090505.htm Researchers have genetically engineered a new laboratory model that enables accurate testing of anti-cancer drugs by mimicking the complexity of human cancers. Using this advanced model, researchers will be able to discover the safest and most effective ways to use promising drugs called MCL-1 inhibitors in the clinic. Thu, 11 Oct 2018 09:05:05 EDT https://www.sciencedaily.com/releases/2018/10/181011090505.htm https://www.sciencedaily.com/releases/2018/10/181004143929.htm A twist on the molecular mechanism of how a new cancer drug works could aid in better identifying the best treatments for patients for an array of cancers. The team identified over 500 sites in DNA that require an enzyme called ATR checkpoint kinase to not break when they are replicated. Thu, 04 Oct 2018 14:39:29 EDT https://www.sciencedaily.com/releases/2018/10/181004143929.htm https://www.sciencedaily.com/releases/2018/09/180910160648.htm Immune checkpoint inhibitors are revolutionizing the treatment of cancer, but new research challenges the central dogma of how these drugs work. This research shows for the first time that often-overlooked immune cells called Natural Killer (NK) cells play a crucial role in responding to checkpoint inhibitors. Mon, 10 Sep 2018 16:06:48 EDT https://www.sciencedaily.com/releases/2018/09/180910160648.htm https://www.sciencedaily.com/releases/2018/08/180829115508.htm The team set out to explore cancer drivers that allow NUT midline carcinoma -- a rare, aggressive cancer that can arise in multiple organs -- to become impervious to drugs. Their results may apply to several forms of cancer fueled by the same mutated driver gene, and their approach may be applicable to other types of cancer whose genomes have been sequenced. Wed, 29 Aug 2018 11:55:08 EDT https://www.sciencedaily.com/releases/2018/08/180829115508.htm https://www.sciencedaily.com/releases/2018/08/180816143054.htm A group of researchers used a systematic approach to get an entirely new look at the way tuberculosis infects people. Their study uncovered interactions between tuberculosis and human proteins that could provide new approaches to combat infection. Thu, 16 Aug 2018 14:30:54 EDT https://www.sciencedaily.com/releases/2018/08/180816143054.htm https://www.sciencedaily.com/releases/2018/07/180726161100.htm Hereditary angioedema is a chronic disorder that can sometimes be life-threatening. Now, a new drug therapy has been successfully tested in an international study. Thu, 26 Jul 2018 16:11:00 EDT https://www.sciencedaily.com/releases/2018/07/180726161100.htm https://www.sciencedaily.com/releases/2018/07/180724105912.htm Researchers have identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication. Tue, 24 Jul 2018 10:59:12 EDT https://www.sciencedaily.com/releases/2018/07/180724105912.htm https://www.sciencedaily.com/releases/2018/07/180720092458.htm A drug currently in clinical trials for treating symptoms of Parkinson's disease may someday have value for treating heart failure, according to results of early animal studies. Fri, 20 Jul 2018 09:24:58 EDT https://www.sciencedaily.com/releases/2018/07/180720092458.htm https://www.sciencedaily.com/releases/2018/05/180502094704.htm An estimated 45 percent of people are at risk of developing knee osteoarthritis (OA) in their lifetime. According to a network meta-analysis research article the nonsteroidal anti-inflammatory drug (NSAID) naproxen was ranked most effective in individual knee OA treatment for improving both pain and function, and is considered a relatively safe and low-cost treatment method. Wed, 02 May 2018 09:47:04 EDT https://www.sciencedaily.com/releases/2018/05/180502094704.htm https://www.sciencedaily.com/releases/2018/05/180501130734.htm Ibuprofen, aspirin, and other non-steroidal anti-inflammatory medications are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs' promising anti-cancer properties have been highlighted by a growing body of data in recent years. However, a new study indicated that non-aspirin NSAID use was associated with shorter overall survival in patients with metastatic renal cell carcinoma (mRCC). Tue, 01 May 2018 13:07:34 EDT https://www.sciencedaily.com/releases/2018/05/180501130734.htm https://www.sciencedaily.com/releases/2018/04/180411110954.htm The class of drugs currently prescribed to treat male erectile dysfunction has been flagged for its potential to be included in new trials for anti-cancer drugs. Wed, 11 Apr 2018 11:09:54 EDT https://www.sciencedaily.com/releases/2018/04/180411110954.htm https://www.sciencedaily.com/releases/2018/03/180307161354.htm Seizure suppression is the focus of an original research -- and they have the pictures to prove it. Their new work sheds new light on epilepsy, a chronic neurological disorder marked by recurrent, unprovoked seizures. Wed, 07 Mar 2018 16:13:54 EST https://www.sciencedaily.com/releases/2018/03/180307161354.htm https://www.sciencedaily.com/releases/2018/03/180305092848.htm New compounds targeting epigenetics have shown remarkable early activity in patients with lymphoma, according to new data. Mon, 05 Mar 2018 09:28:48 EST https://www.sciencedaily.com/releases/2018/03/180305092848.htm https://www.sciencedaily.com/releases/2018/01/180125230343.htm Researchers have found that Ewing sarcoma cells die if an enzyme called CDK12 is knocked out genetically or chemically inhibited. What's more, when a CDK12 inhibitor is combined with another drug, called a PARP inhibitor, the two drugs double down to deliver a lethal punch to Ewing sarcoma cells. Thu, 25 Jan 2018 23:03:43 EST https://www.sciencedaily.com/releases/2018/01/180125230343.htm https://www.sciencedaily.com/releases/2018/01/180124114135.htm Two different proteins work separately as well as synergistically to feed a small pool of stem cells that help bladder cancer resist chemotherapy, research suggests. The finding could lead to new targets to fight this deadly disease and potentially other cancers as well. Wed, 24 Jan 2018 11:41:35 EST https://www.sciencedaily.com/releases/2018/01/180124114135.htm https://www.sciencedaily.com/releases/2017/11/171103085852.htm Patients with advanced breast cancer who are treated with a combination of drugs that target specific molecules important for cancer development and also the hormones that are driving it are at increased risk of suffering adverse side effects. Fri, 03 Nov 2017 08:58:52 EDT https://www.sciencedaily.com/releases/2017/11/171103085852.htm https://www.sciencedaily.com/releases/2017/08/170828094844.htm Ibuprofen is associated with increased blood pressure and hypertension compared to celecoxib in patients with osteoarthritis or rheumatoid arthritis and increased risk of cardiovascular disease, according to new research. Mon, 28 Aug 2017 09:48:44 EDT https://www.sciencedaily.com/releases/2017/08/170828094844.htm https://www.sciencedaily.com/releases/2017/08/170816134648.htm A new study explains why CDK4/6 inhibitors can shrink tumor in some advanced breast cancers. CDK4/6 inhibitors trigger the immune system to attack tumor cells. CDK4/6 inhibitors can also enhance anti-cancer effect of immunotherapy agents. Wed, 16 Aug 2017 13:46:48 EDT https://www.sciencedaily.com/releases/2017/08/170816134648.htm https://www.sciencedaily.com/releases/2017/08/170815111010.htm Some epigenetic pharmaceuticals have the potential to be used as broad spectrum antivirals, according to a new study. The study demonstrated that histone methyltransferases EZH2/1 inhibitors, which are being used in cancer clinical trials, have activity against a variety of viruses, including herpes simplex virus (HSV). Tue, 15 Aug 2017 11:10:10 EDT https://www.sciencedaily.com/releases/2017/08/170815111010.htm https://www.sciencedaily.com/releases/2017/07/170725204234.htm Following the terrorist attacks in Paris and Nice, French experts outline the country's medical response to terrorism in a new report. Tue, 25 Jul 2017 20:42:34 EDT https://www.sciencedaily.com/releases/2017/07/170725204234.htm https://www.sciencedaily.com/releases/2017/07/170721084701.htm In preclinical studies, tumors that consitutively expressed the protein indoleamine 2,3-dioxygenase (IDO1) responded to the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) and had improved infiltration of certain subsets of T cells, making them more likely to respond to anti-PD1 therapies, report researcher. Fri, 21 Jul 2017 08:47:01 EDT https://www.sciencedaily.com/releases/2017/07/170721084701.htm https://www.sciencedaily.com/releases/2017/07/170720095225.htm Scientists have found a new way to protect stem cells from harsh inflammation during wound repair. Researchers have discovered that treating mice with a common anti-inflammatory drug called celecoxib promoted stem cell survival and healing when they injected the cells into wounds. Thu, 20 Jul 2017 09:52:25 EDT https://www.sciencedaily.com/releases/2017/07/170720095225.htm